Back to search
Gastro Esophageal Reflux Disease PPI Non-Responders
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Gastro Esophageal Reflux Disease PPI Non-Responders trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Gastro Esophageal Reflux Disease PPI Non-Responders trials you may qualify forThe prevalence of GERD is estimated to be as high as 20% in the US, and up to 50% remain symptomatic on proton pump inhibitor (PPI) therapy. The clinical approa…
Gastroesophageal reflux disease (GERD) is a common chronic condition, affecting approximately 20% of the American adult population. Proton pump inhibitors (PPIs…
To understand the dose-response characteristics of PF-00885706 for efficacy in terms of symptomatic relief when used as add-on treatment to esomeprazole 20mg (s…